-
EP4058486
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4058486
| EP4058486 - ANTIBODY-PAYLOAD CONJUGATES WITH ENHANCED DELIVERY DOMAIN AND USES THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 19.08.2022 Database last updated on 25.09.2024 | |
| Former | The international publication has been made Status updated on 21.05.2021 | Most recent event Tooltip | 24.01.2024 | The date on which the examining division becomes responsible, has been established | 24.01.2024 | Amendment by applicant | Applicant(s) | For all designated states Iprogen Biotech Inc. 8531 Commerce Crt. Burnaby, British Columbia V5A 4N4 / CA | [2022/38] | Inventor(s) | 01 /
LEE, Keun Ho 2270 Stanwood Avenue Coquitlam, British Columbia V3K 3A6 / CA | 02 /
LIN, Leo Yen-Cheng 16618 79A Avenue Surrey, British Columbia V4N 0H9 / CA | 03 /
VAIDYANATHAN, Ranjani 907 - 725 West 70th Avenue Vancouver, British Columbia V6P 2X3 / CA | 04 /
LARIO, Paula 201 - 2080 East Kent Ave South Vancouver, British Columbia V5P 4X2 / CA | [2022/38] | Representative(s) | Wilson, Justin Scott Withers & Rogers LLP 2 London Bridge London SE1 9RA / GB | [2022/38] | Application number, filing date | 19952147.7 | 12.11.2019 | [2022/38] | WO2019CA51612 | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021092672 | Date: | 20.05.2021 | Language: | EN | [2021/20] | Type: | A1 Application with search report | No.: | EP4058486 | Date: | 21.09.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 20.05.2021 takes the place of the publication of the European patent application. | [2022/38] | Search report(s) | International search report - published on: | CA | 20.05.2021 | (Supplementary) European search report - dispatched on: | EP | 17.07.2023 | Classification | IPC: | C07K14/47, C07K19/00, A61K47/68, A61P31/00, A61P35/00, A61P37/06, A61K47/64, C07K16/28, C07K16/32, C07K16/30 | [2023/33] | CPC: |
A61P31/00 (EP);
C07K16/28 (EP,US);
A61K47/64 (EP,US);
A61K47/68 (US);
A61P35/00 (EP);
A61P37/02 (US);
A61P37/06 (EP);
C07K14/4723 (EP);
C07K16/2803 (EP);
C07K16/2863 (EP);
C07K16/2887 (EP);
C07K16/30 (EP);
C07K16/3007 (EP);
C07K16/32 (EP);
C07K2317/622 (EP);
|
| Former IPC [2022/38] | C07K19/00, A61K47/68, A61P31/00, A61P35/00, A61P37/06 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/38] | Title | German: | ANTIKÖRPER-NUTZLAST-KONJUGATE MIT VERBESSERTER ABGABEDOMÄNE UND DEREN VERWENDUNGEN | [2022/38] | English: | ANTIBODY-PAYLOAD CONJUGATES WITH ENHANCED DELIVERY DOMAIN AND USES THEREOF | [2022/38] | French: | CONJUGUÉS ANTICORPS-CHARGE UTILE AYANT UN DOMAINE D'ADMINISTRATION AMÉLIORÉ ET LEURS UTILISATIONS | [2022/38] | Entry into regional phase | 09.06.2022 | National basic fee paid | 09.06.2022 | Search fee paid | 09.06.2022 | Designation fee(s) paid | 09.06.2022 | Examination fee paid | Examination procedure | 09.06.2022 | Examination requested [2022/38] | 23.01.2024 | Amendment by applicant (claims and/or description) | 23.01.2024 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 09.06.2022 | Renewal fee patent year 03 | 15.09.2022 | Renewal fee patent year 04 | 15.11.2023 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2009018500 (UNIV JOHNS HOPKINS [US], et al) [A] 1-15* Whole document, especially the claims. *; | [A]WO2010129033 (CALMUNE CORP [US], et al) [A] 1-15 * Whole document, especially the claims. *; | [A]WO2018169953 (SCHERER TECHNOLOGIES LLC R P [US]) [A] 1-15 * Whole document, especially §0228 and claims. *; | [A] - XUEJING YAO ET AL, "A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity", BREAST CANCER RESEARCH AND TREATMENT, New York, (20150808), vol. 153, no. 1, doi:10.1007/s10549-015-3503-3, ISSN 0167-6806, pages 123 - 133, XP055370764 [A] 1-15 * Whole document, especially the figures. * DOI: http://dx.doi.org/10.1007/s10549-015-3503-3 | [A] - LI X ET AL, "Solution structures of human LL-37 fragments and NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, (20060503), vol. 128, no. 17, doi:10.1021/JA0584875, ISSN 0002-7863, pages 5776 - 5785, XP002410495 [A] 1-15 * abstract * DOI: http://dx.doi.org/10.1021/ja0584875 | [A] - KURODA KENGO ET AL, "The Human Cathelicidin Antimicrobial Peptide LL-37 and Mimics are Potential Anticancer Drugs", FRONTIERS IN ONCOLOGY, (20150630), vol. 5, doi:10.3389/fonc.2015.00144, XP055822431 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.3389/fonc.2015.00144 | [A] - TANG XIAO ET AL, "P2X7 Receptor Regulates Internalization of Antimicrobial Peptide LL-37 by Human Macrophages That Promotes Intracellular Pathogen Clearance", THE JOURNAL OF IMMUNOLOGY, US, (20150801), vol. 195, no. 3, doi:10.4049/jimmunol.1402845, ISSN 0022-1767, pages 1191 - 1201, XP093059920 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.4049/jimmunol.1402845 | International search | [XY]WO2009018500 (UNIV JOHNS HOPKINS [US], et al) [X] 1-35,37-47 *[00290], [0338], [0487], [0523]-[0555] * [Y] 36; | [Y] - YAO, X. et al., "A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity", Breast Cancer Research and Treatment, (20150818), vol. 153, no. 1, doi:10.1007/s10549-015-3503-3, ISSN 01676806, pages 123 - 133, XP055370764 [Y] 36 *Whole document * DOI: http://dx.doi.org/10.1007/s10549-015-3503-3 | [A] - KURODA, K. et al., "The human cathelicidin antimicrobial peptide LL-37 and mimics are potential anticancer drugs", Frontiers in Oncology, (20150630), vol. 5, no. 144, ISSN 2234943X, pages 1 - 10, XP055822431 [A] 1-47 *Whole document * DOI: http://dx.doi.org/10.3389/fonc.2015.00144 |